117 related articles for article (PubMed ID: 18453023)
1. Assessing the impact of FDG-PET in the management of anal cancer.
Nguyen BT; Joon DL; Khoo V; Quong G; Chao M; Wada M; Joon ML; See A; Feigen M; Rykers K; Kai C; Zupan E; Scott A
Radiother Oncol; 2008 Jun; 87(3):376-82. PubMed ID: 18453023
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
3. Role of positron emission tomography-computed tomography in the management of anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography/computed tomography in the staging and treatment of anal cancer.
Sveistrup J; Loft A; Berthelsen AK; Henriksen BM; Nielsen MB; Engelholm SA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):134-41. PubMed ID: 22000745
[TBL] [Abstract][Full Text] [Related]
5. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis.
Jones M; Hruby G; Solomon M; Rutherford N; Martin J
Ann Surg Oncol; 2015 Oct; 22(11):3574-81. PubMed ID: 25652048
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET/CT in the evaluation of anal carcinoma.
Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
[TBL] [Abstract][Full Text] [Related]
8. Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
Piperkova E; Raphael B; Altinyay M; Castellon I; Libes R; Sandella N; Abdel-Dayem H
J BUON; 2006; 11(4):523-7. PubMed ID: 17309188
[TBL] [Abstract][Full Text] [Related]
9. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up.
Saboo SS; Zukotynski K; Shinagare AB; Krajewski KM; Ramaiya N
Abdom Imaging; 2013 Aug; 38(4):728-35. PubMed ID: 23011550
[TBL] [Abstract][Full Text] [Related]
10. Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
Iagaru A; Kundu R; Jadvar H; Nagle D
Hell J Nucl Med; 2009; 12(1):26-9. PubMed ID: 19330178
[TBL] [Abstract][Full Text] [Related]
11. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
[TBL] [Abstract][Full Text] [Related]
13. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
[TBL] [Abstract][Full Text] [Related]
14. F-18 FDG PET/CT imaging of anal canal squamous cell carcinoma.
Nguyen BD; Ram PC; Roarke MC
Clin Nucl Med; 2007 Mar; 32(3):234-6. PubMed ID: 17314608
[No Abstract] [Full Text] [Related]
15. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
[TBL] [Abstract][Full Text] [Related]
16. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
Schwarz JK; Siegel BA; Dehdashti F; Myerson RJ; Fleshman JW; Grigsby PW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):180-6. PubMed ID: 17996387
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma.
Goldman KE; White EC; Rao AR; Kaptein JS; Lien WW
Pract Radiat Oncol; 2016; 6(5):e149-e154. PubMed ID: 26948134
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
[TBL] [Abstract][Full Text] [Related]
19. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
[TBL] [Abstract][Full Text] [Related]
20. Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients.
Slim N; Passoni P; Incerti E; Tummineri R; Gumina C; Cattaneo GM; De Nardi P; Canevari C; Fiorino C; Ronzoni M; Tamburini AM; Burgio V; Gianolli L; Di Muzio N
Sci Rep; 2020 Sep; 10(1):14613. PubMed ID: 32884036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
